News

Ceres Nanosciences receives $500,000 grant to deploy wastewater surveillance products for global health security.

Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, announced today that it has received a $500,000 grant award from the Gates Foundation. This funding will support the deployment of Ceres’ wastewater biosecurity products to global health testing sites across Africa and India.

Global biosecurity has become a top priority, and wastewater surveillance for pathogens in low- and middle-income countries (LMICs) is crucial for pandemic preparedness and prevention. There is a significant need for standardized, low-cost, and easy-to-use wastewater sample processing methods across diverse geographic locations.

This funding will focus on establishing a sustainable supply chain for wastewater testing tools, ensuring that LMICs can continue to monitor priority pathogens beyond the life of the grant. By lowering barriers to adoption, Ceres aims to strengthen national disease surveillance systems and accelerate progress towards global health security.

“Global biosecurity has become a top priority, and wastewater surveillance is one of the most effective ways to monitor pathogens of concern at the population level,” said Ross Dunlap, CEO of Ceres Nanosciences. “By deploying our sample processing products to sites across Africa and India, we can help public agencies act faster, respond to outbreaks earlier, and build resilient surveillance systems that protect millions of lives. We are grateful to the Gates Foundation for supporting this critical need.”

 

Read more here.

Recent News

10/13/2025

InBio Secures $3.5 Million NIH Grant to Advance Allergy Research

InBio, a global leader in allergy research, was recently awarded a $3.5 million R01 grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This funding supports a groundbreaking initiative to develop innovative immunotherapeutic tools targeting allergens from house dust mites, cats, and dogs—major contributors to

10/09/2025

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs

AstraZeneca announces that it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500m to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments. This is part of the historic $50 billion investment announced in July 2025. The new facility will be located at

10/09/2025

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the successful completion of the analytical validation of a cheek swab collection method for testing patients for both clinical trial usage as well as future commercial application. This major step marks a